hepcinat-plus in india

Hepcinat-plus

• Hepcinat plus contains active ingredients of Sofosbuvir 400mg and Daclatasvir 60mg.  

• Hepcinat plus is a film coated tablet in which it composed of white to yellow colour solid and freely soluble in methanol and water. Hepcinat plus is a oval shape white colour tablet.

                Hepcinat-plus

                                                                     

          Absorption

• Peak plasma concentration of Hepcinat Plus ;
• Sofosbuvir: 0.5 to 2 hours
• Daclatasvir: within 2 hours
• Food should not be considered majorly, it should be administered with or without food.
• Oral bioavailability occurred in Daclatasvir is 67%

       Metabolism of Hepcinat Plus 

• Metabolism of sofosbuvir is involved in the liver, with the help of carboxyl esterase 1 or cathepsin A
• Nearly 99% of Daclatasvir is binding to protein and it is the substrate of CYP3A.

      Hepcinat plus tablet caused side effects

• Neutropenia
• Myalgia
• Irritability
• Pancytopenia
• Elevation of bilirubin, creatine kinase, lipase, AST & ALT
• HBV reoccurrence may occur
• Serious bradycardia while combining with amiodarone
• Fatigue
• A headache
• Insomnia
• Nausea
• Pruritus

Food-drug interaction:

• There is no possible food-drug interaction occurs during the therapy.
• Diet should be maintained after getting advice from the physician
• While concomitant with ribavirin, should not be taken on an empty stomach.

myhep-dvir tablets price in india

myhep-dvir

•  myhep dvir tablet is a effective combination of two esteemed anti-viral compounds   like Sofosbuvir & Daclatasvir. 
•  Sofosbuvir is a present as prodrug and exhibits its action by converting into active   moiety. 
•  Daclatasvir is not used as single, must be use in combination of other anti-viral agent   called sofosbuvir and expels prominent effect against hepatitis virus

                                                              myhep dvir

MECHANISM OF ACTION

• MYHEP DVIR notwithstanding tablet has two fragments Sofosbuvir and Daclatasvir 
• Daclatasvir performs Non essential 5A protein is the key for viral duplication. Daclatasvir interfere with the activity of NS5A protein, this may prompts viral destruction. 
• Sofosbuvir is a prohibitor of nucleotide basic, especially blocks HCV non-helper protein 5B RNA subordinate RNA polymerase. 
• Sofosbuvir encounter intracellular absorption, which convey pharmacologically powerful compound like uridine basic triphosphate 
• Sofosbuvir intercede into RNA of hepatitis C contamination with the help of NS5B polymerase. This may goes about as chain eliminator.

 FOOD DRUG INTERACTION

• Food drug interaction is not possible during the therapy. 
• Maintained in diet after getting advice from the physician 
• Concomitant use of ribavirin, should not be taken on an empty stomach.

 SAFETY MEASURES

• This adverse condition may reduced by; 
• Examine the patients who are going to receive the MYHEP DVIR tablet formerly with HBV infection present or not. The patients who are not taking anti-hepatitis B viral drugs may occur. 
• To avoid this condition, patients must be investigating by undergone liver function test.

Metabolism

• Metabolism of sofosbuvir is involved in liver, with the help of carboxyl esterase 1 or cathepsin A 
• Nearly 99% of Daclatasvir is binding to protein and it is substrate of CYP3A.

MYHEP DVIR dosing regimen;

• The usual dose of MYHEP DVIR tablet is one tablet should be taken as a single dose by administering with food or without food. 
• On severe condition, MYHEP DVIR must be combine with ribavirin. Patients suffering in HCV genotype I or III with decompensated cirrhosis or post transplantation; the initial dose of ribavirin is 600mg as a single dose, elevating dose up to 1000mg. In compensated cirrhosis; the starting dose of ribavirin should be calculated on the basis of body weight of the suspected patients. In patient with weight of at least 75kg: 1200mg of ribavirin should be considered.

XBIRA 250mg tablets

XBIRA 250mg

• Tabletele Xbira 250 mg conțin un ingredient activ cunoscut ca acetat de abirateronă care are activitate antitumorală împotriva cancerului de prostată.
• Xbira este un derivat de androstene, care implică procesul de interdicție a steroizilor 17-alfa hidroxilază și conține activitate antineoplazică. 
•  Abirateron acetat este o tabletă orală care este o formă steroidică activă de acetat de ester cunoscut sub numele de Abiraterone cu activitate anti-androgenă.

XBIRA 250mg

MĂSURI DE SIGURANȚĂ

• Xbira inhibă CYP17, determină creșterea nivelurilor de mineralocorticoizi care duc la hipoparathyroidism, hipertensiune și retenție de lichide.

• Administrarea concomitentă de Xbira cu corticosteroizi conduce la diminuarea hormonului adrenocorticotrofic, care se termină ca o reducere a amplorii și severității acestor efecte secundare.

• Controlați tensiunea arterială și nivelurile corecte de potasiu și lichid, dacă este necesar.

 DIFERITE EFECTE APROAPATE

•  Oboseală
• Durere articulară, umflare sau disconfort
• Hot flush
• hipertensiune
• Diaree
• Vărsături
• Tuse
• hipertensiune
• dispnee
• Infectii ale tractului urinar
• Contuzie

Depozitare și manipulare

• Containerul de tablete Xbira trebuie păstrat la temperaturi cuprinse între 20 ° C și 25 ° C
• Păstrați recipientul fără umiditate, căldură și lumină